4.7 Article

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

期刊

CELL DEATH & DISEASE
卷 13, 期 10, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41419-022-05287-6

关键词

-

资金

  1. Slovenian Research Agency [P1-0208, NC-0004, P3-0289]
  2. Ministry of Education, Science, and Sport (MIZS)
  3. European Regional Development Fund [P1-0208, OP20.05187 RI-SI-EATRIS]

向作者/读者索取更多资源

Chronic lymphocytic leukemia (CLL) is a type of hematological cancer involving B lymphocytes, and venetoclax is a commonly used targeted therapy. This study found that certain molecular mechanisms in CLL cells can lead to resistance to venetoclax, but targeting these mechanisms can overcome the resistance.
Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity. This is also true for the Bcl-2 antagonist venetoclax. We investigated the molecular mechanisms that drive venetoclax resistance in CLL, with a dear focus to provide new strategies to successfully combat it. Activation of CLL cells with IFN gamma, PMA/ionomycin, and sCD4OL diminished the cytotoxicity of venetoclax. We demonstrated that the metabolic activity of cells treated with 1 nM venetoclax alone was 48% of untreated cells, and was higher for cells co-treated with IFN gamma (110%), PMA/ionomycin (78%), and sCD4OL (62%). As of molecular mechanism, we showed that PMA/ionomycin and sCD4OL triggered translocation of NFKB in primary CLL cells, while IFN gamma activated p38 MAPK, suppressed spontaneous and venetoclax-induced apoptosis and induced formation of the immunoproteasome. Inhibition of immunoproteasome with ONX-0914 suppressed activity of immunoproteasome and synergized with venetoclax against primary CLL cells. On the other hand, inhibition of p38 MAPK abolished cytoprotective effects of IFN gamma. We demonstrated that venetoclax-resistant (MEC-1 VER) cells overexpressed p38 MAPK and p-Bcl-2 (Ser70), and underexpressed Mcl-1, Bax, and Bak. Inhibition of p38 MAPK or immunoproteasome triggered apoptosis in CLL cells and overcame the resistance to venetoclax of MEC-1 VER cells and venetoclax-insensitive primary CLL cells. In conclusion, the p38 MAPK pathway and immunoproteasome represent novel targets to combat venetoclax resistance in CLL.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据